Drupal.behaviors.print = function(context) {window.print();window.close();}>
MDRNA Inks Early-Stage Research Deal with Pfizer
April 08, 2010
MDRNA Inks Early-Stage Research Deal with Pfizer
Under the deal, Pfizer will evaluate MDRNA's proprietary siRNA constructs and delivery technology.
Full-text access for premium subscribers only.
Existing premium subscribers
login here
.
New to GenomeWeb?
Register here
quickly.
Related Stories
Snapshot: Partnership Goals, Track Records in the RNAi/miRNA Space
July 22, 2010 / Gene Silencing News
Tacere Said to be Looking for New Partner for HCV Drug Candidate
June 21, 2012 / Gene Silencing News
Despite Recent Changes in Plans, Big Pharma Maintains RNAi Partnerships
December 9, 2010 / Gene Silencing News
Tekmira Inks siRNA Delivery Tech Deal with Pfizer, Reports Higher Q4 Losses on R&D Spending
March 18, 2010 / Gene Silencing News
MDRNA Inks Second 'Early Collaborative Effort,' Releases Preclinical Cancer Data
January 14, 2010 / Gene Silencing News